Product logins

Find logins to all Clarivate products below.


Peripheral Arterial Disease – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PAD for each country, as well as annualized case counts projected to the national population.

Most patient populations in the mature pharmaceutical markets are forecast over a period of 20 years; in other countries, forecasts cover a 10-year period. In addition to forecasting prevalent patient populations, we calculate the number of drug-treatment opportunities in specific lines of therapy in the mature pharmaceutical markets.

Clarivate Epidemiology’s PAD forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with PAD?
  • Of all people with PAD, how many in each country have been formally diagnosed?
  • Of all people diagnosed with PAD, how many in the mature pharmaceutical markets are drug-treated?
  • How will demographic trends such as population aging and improving life expectancy affect the epidemiology of PAD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the mature pharmaceutical markets. These patient flows are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology provides at least 10 years of forecast data for the following PAD patient populations:

  • Total prevalent cases.
  • Diagnosed prevalent cases.

… and many more (details available on request).

Note: Coverage may vary by country and region.

Related Market Assessment Reports

Report
Acute Coronary Syndrome – Landscape & Forecast – Disease Landscape & Forecast (G7)
Acute coronary syndrome (ACS) is a leading cause of morbidity and mortality in developed countries. Despite aggressive management of atherothrombotic risk factors through LDL-C lowering, blood-…
Report
Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Pulmonary hypertension (PH) is a high-burden condition with significant unmet needs across the major markets. Despite its small patient pool, the commercial potential for PH therapies is…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Hypertension – Unmet Need – Unmet Need – Resistant Hypertension (US/EU)
Resistant hypertension (RHTN) has become a critical focus within the cardiovascular market because a substantial proportion of patients remain uncontrolled despite multidrug therapy, with…